Literature DB >> 24096148

Review of mass spectrometry-based metabolomics in cancer research.

David B Liesenfeld1, Nina Habermann, Robert W Owen, Augustin Scalbert, Cornelia M Ulrich.   

Abstract

Metabolomics, the systematic investigation of all metabolites present within a biologic system, is used in biomarker development for many human diseases, including cancer. In this review, we investigate the current role of mass spectrometry-based metabolomics in cancer research. A literature review was carried out within the databases PubMed, Embase, and Web of Knowledge. We included 106 studies reporting on 21 different types of cancer in 7 different sample types. Metabolomics in cancer research is most often used for case-control comparisons. Secondary applications include translational areas, such as patient prognosis, therapy control and tumor classification, or grading. Metabolomics is at a developmental stage with respect to epidemiology, with the majority of studies including less than 100 patients. Standardization is required especially concerning sample preparation and data analysis. In the second part of this review, we reconstructed a metabolic network of patients with cancer by quantitatively extracting all reports of altered metabolites: Alterations in energy metabolism, membrane, and fatty acid synthesis emerged, with tryptophan levels changed most frequently in various cancers. Metabolomics has the potential to evolve into a standard tool for future applications in epidemiology and translational cancer research, but further, large-scale studies including prospective validation are needed. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24096148      PMCID: PMC3912559          DOI: 10.1158/1055-9965.EPI-13-0584

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  143 in total

Review 1.  Phases of biomarker development for early detection of cancer.

Authors:  M S Pepe; R Etzioni; Z Feng; J D Potter; M L Thompson; M Thornquist; M Winget; Y Yasui
Journal:  J Natl Cancer Inst       Date:  2001-07-18       Impact factor: 13.506

Review 2.  The grand challenge to decipher the cancer proteome.

Authors:  Samir Hanash; Ayumu Taguchi
Journal:  Nat Rev Cancer       Date:  2010-09       Impact factor: 60.716

3.  Bladder cancer determination via two urinary metabolites: a biomarker pattern approach.

Authors:  Zhenzhen Huang; Lin Lin; Yao Gao; Yongjing Chen; Xiaomei Yan; Jinchun Xing; Wei Hang
Journal:  Mol Cell Proteomics       Date:  2011-07-28       Impact factor: 5.911

Review 4.  Cancer omics: from regulatory networks to clinical outcomes.

Authors:  Binhua Tang; Pei-Yin Hsu; Tim H-M Huang; Victor X Jin
Journal:  Cancer Lett       Date:  2012-11-29       Impact factor: 8.679

5.  Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer.

Authors:  Zhuoling An; Yanhua Chen; Ruiping Zhang; Yongmei Song; Jianghao Sun; Jiuming He; Jinfa Bai; Lijia Dong; Qimin Zhan; Zeper Abliz
Journal:  J Proteome Res       Date:  2010-08-06       Impact factor: 4.466

6.  Serum 27-nor-5β-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer.

Authors:  Jing Chen; Xiaoyan Zhang; Rui Cao; Xin Lu; Sumin Zhao; Agnes Fekete; Qiang Huang; Philippe Schmitt-Kopplin; Yisheng Wang; Zhiliang Xu; Xiaoping Wan; Xiaohua Wu; Naiqing Zhao; Congjian Xu; Guowang Xu
Journal:  J Proteome Res       Date:  2011-04-19       Impact factor: 4.466

7.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

8.  Ultra-high performance liquid chromatography-mass spectrometry for the metabolomic analysis of urine in colorectal cancer.

Authors:  Yan-Lei Ma; Huan-Long Qin; Wei-Jie Liu; Jia-Yuan Peng; Long Huang; Xiao-Ping Zhao; Yi-Yu Cheng
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

9.  Metabolic profiling reveals key metabolic features of renal cell carcinoma.

Authors:  Gareth Catchpole; Alexander Platzer; Cornelia Weikert; Carsten Kempkensteffen; Manfred Johannsen; Hans Krause; Klaus Jung; Kurt Miller; Lothar Willmitzer; Joachim Selbig; Steffen Weikert
Journal:  J Cell Mol Med       Date:  2011-01       Impact factor: 5.310

10.  A novel serum metabolomics-based diagnostic approach for colorectal cancer.

Authors:  Shin Nishiumi; Takashi Kobayashi; Atsuki Ikeda; Tomoo Yoshie; Megumi Kibi; Yoshihiro Izumi; Tatsuya Okuno; Nobuhide Hayashi; Seiji Kawano; Tadaomi Takenawa; Takeshi Azuma; Masaru Yoshida
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

View more
  53 in total

1.  Untargeted Tumor Metabolomics with Liquid Chromatography-Surface-Enhanced Raman Spectroscopy.

Authors:  Lifu Xiao; Chuanqi Wang; Chen Dai; Laurie E Littlepage; Jun Li; Zachary D Schultz
Journal:  Angew Chem Int Ed Engl       Date:  2020-01-27       Impact factor: 15.336

Review 2.  Metabolomic signature of brain cancer.

Authors:  Renu Pandey; Laura Caflisch; Alessia Lodi; Andrew J Brenner; Stefano Tiziani
Journal:  Mol Carcinog       Date:  2017-07-17       Impact factor: 4.784

3.  Candidate serum metabolite biomarkers for differentiating gastroesophageal reflux disease, Barrett's esophagus, and high-grade dysplasia/esophageal adenocarcinoma.

Authors:  Matthew F Buas; Haiwei Gu; Danijel Djukovic; Jiangjiang Zhu; Lynn Onstad; Brian J Reid; Daniel Raftery; Thomas L Vaughan
Journal:  Metabolomics       Date:  2017-01-20       Impact factor: 4.290

4.  Metabolomics and transcriptomics identify pathway differences between visceral and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study.

Authors:  David B Liesenfeld; Dmitry Grapov; Johannes F Fahrmann; Mariam Salou; Dominique Scherer; Reka Toth; Nina Habermann; Jürgen Böhm; Petra Schrotz-King; Biljana Gigic; Martin Schneider; Alexis Ulrich; Esther Herpel; Peter Schirmacher; Oliver Fiehn; Johanna W Lampe; Cornelia M Ulrich
Journal:  Am J Clin Nutr       Date:  2015-07-08       Impact factor: 7.045

5.  A systematic review on metabolomics-based diagnostic biomarker discovery and validation in pancreatic cancer.

Authors:  Nguyen Phuoc Long; Sang Jun Yoon; Nguyen Hoang Anh; Tran Diem Nghi; Dong Kyu Lim; Yu Jin Hong; Soon-Sun Hong; Sung Won Kwon
Journal:  Metabolomics       Date:  2018-08-10       Impact factor: 4.290

6.  Nutritional metabolomics and breast cancer risk in a prospective study.

Authors:  Mary C Playdon; Regina G Ziegler; Joshua N Sampson; Rachael Stolzenberg-Solomon; Henry J Thompson; Melinda L Irwin; Susan T Mayne; Robert N Hoover; Steven C Moore
Journal:  Am J Clin Nutr       Date:  2017-06-28       Impact factor: 7.045

7.  Technical Challenges in Mass Spectrometry-Based Metabolomics.

Authors:  Fumio Matsuda
Journal:  Mass Spectrom (Tokyo)       Date:  2016-11-25

Review 8.  Metabolomics in epidemiologic research: challenges and opportunities for early-career epidemiologists.

Authors:  Eline H van Roekel; Erikka Loftfield; Rachel S Kelly; Oana A Zeleznik; Krista A Zanetti
Journal:  Metabolomics       Date:  2019-01-07       Impact factor: 4.290

Review 9.  Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Authors:  Rachel S Kelly; Matthew G Vander Heiden; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-06       Impact factor: 4.254

Review 10.  Diet, nutrition, and cancer: past, present and future.

Authors:  Susan T Mayne; Mary C Playdon; Cheryl L Rock
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.